-+ 0.00%
-+ 0.00%
-+ 0.00%

IDEAYA to Present Updated Melanoma Drug Data at Upcoming ESMO Congress

Benzinga·10/19/2026 10:07:38
Listen to the news

IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a leading precision medicine oncology company, today announced updated clinical data from three ongoing studies evaluating darovasertib in metastatic and primary uveal melanoma (UM) that will be presented at the European Society for Medical Oncology (ESMO) Congress 2026, taking place on October 23–27 in Madrid, Spain. The updates will include Phase 2 expansion data from OptimUM-01 in HLA-A*02:01-positive patients with metastatic uveal melanoma (mUM), subgroup analyses from the registrational Phase 2/3 OptimUM-02 trial in first line (1L) HLA-A*02:01-negative mUM and follow-up data from the Phase 2 OptimUM-09 trial evaluating neoadjuvant darovasertib in patients with primary UM.